Kathy LaPorte

Ms. LaPorte previously served as Chief Business Officer and Chief Executive Officer of Nodality Inc. She was a Founding Partner of New Leaf Venture Partners, which was a spin-out from the Sprout Group, where she served as a General Partner. Ms. LaPorte was also a Co-Founder of Health Tech Capital. She has extensive Board experience at numerous public and private companies, and currently serves on the Boards of Elysium Therapeutics, Precipio Diagnostics, D2G Oncology, and Bolt Biotherapeutics. Ms. LaPorte received her Bachelor of Science in Biology from Yale University and a Master of Business Administration from the Stanford University Graduate School of Business.